Navigation Links
BrainCells Inc. Expands Series B Financing to $50 Million
Date:4/17/2008

SAN DIEGO, April 17 /PRNewswire/ -- BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today that it raised an additional $20 million in an extension of its Series B financing, bringing the total to $50 million. New investor, New Enterprise Associates (NEA), along with current investors and Alexandria Real Estate Equities, Inc. participated in the extension. Other investors that participated in the Series B included MedImmune Ventures, Oxford Bioscience Partners, Technology Partners, Pappas Ventures and NeuroVentures. The financing will be used to continue clinical development of BCI's product candidates including a Phase 2 trial with BCI-540, and to identify additional assets to further expand its pipeline.

As part of the financing extension, BCI announced the addition of Chuck Newhall, general partner and co-founder of NEA, to its Board of Directors. Prior to NEA, he was a Vice President at T. Rowe Price Associates. Before that, Mr. Newhall founded the Mid-Atlantic Venture Capital Association (MAVA) and currently serves as Chairman Emeritus. His board memberships include Bravo by ElderHealth, CoGenesys, Hospital Partners of America, Pharmos, Sensors for Medicine & Science, Supernus Pharmaceuticals, TargetRx, Trine Pharmaceuticals, and Vitae Pharmaceuticals.

"Only weeks after closing our first round of the Series B financing, we are thrilled with the result of the second close and bringing in the support of NEA, another high-quality investor," said Jim Schoeneck, CEO of BCI. "Chuck's decades of experience in the industry will be a tremendous asset to the company as we build momentum in the clinic this year."

BCI recently initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression. The Company in-licensed BCI-540 in
'/>"/>

SOURCE BrainCells Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
4. BioLife Solutions Expands Scientific Advisory Board
5. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
6. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
7. Pharsight Expands Strategic Consulting Services Team
8. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
9. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
10. AQUISS Expands Into Significant New Territory
11. NanoBio Expands Drug Development Team for Its Anti-Infective Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... fluid applications and designed for continuous operation up to 1500 bar. The sanitary ... safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ...
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) ... including accrued interest, of its 2008 Convertible,Notes which ... cash payment of,approximately $11.0 million. The Company currently ... this last piece of current debt provides the ...
... #58177-320-04 & 58177-330-04 ... Lot Numbers listed below, ST. LOUIS, ... specific additional lots of morphine,sulfate 60 mg extended release tablets, and ... precaution, due to the,possible presence of oversized tablets. Oversized tablets may ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... Officer of Alexion,Pharmaceuticals, will present at the William ... 9:10 a.m., local time (10:10 a.m., eastern) on,Thursday, ... Mr. Sinha,s remarks will be available live. You ...
Cached Biology Technology:Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... DNA sequencing technologies have enormous potential for the ... these new technologies, researchers are able to greatly ... key to applications including plant breeding and physiology. ... (or phylogenetic) relationships among different plant species have ...
... is most often linked to excessive food intake or not ... often result in failed weight loss or weight regain in ... encourage your cat to get more exercise? Researchers from ... maintain healthy body weight in cats, looked at a previously ...
... , UK British start-ups Straw Fuels and ... month in an award-scheme supported by the EU,s ... start-up AdFerTech took home the Climate-KIC Early Stage ... the 20.000 first stage of Climate-KIC,s pan-European start-up ...
Cached Biology News:Sequencing hundreds of nuclear genes in the sunflower family now possible 2Sequencing hundreds of nuclear genes in the sunflower family now possible 3Smaller meals more times per day may curb obesity in cats 2Smaller meals more times per day may curb obesity in cats 3Liquor converter, BBQ logs win €20K prizes at UK innovation showcase 2
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-DM 2 x 109 cells...
...
...
... III) from E. coli is an endoribonuclease ... dsRNA fragments that have 2-base, 3'-overhangs. ... fragments of 12-15 bp. RNase III ... ribonucleotides as well as DuraScript™ RNA, produced ...
Biology Products: